Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Meacham argues Regeneron's Eylea franchise and melanoma pipeline optionality leave it well-positioned, raising his price target to $700 from $600 after a roughly 55% stock pullback since last year ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Neutral to Buy. There are 2,406 funds or institutions reporting positions in ...

--Down 41.85% from 52 weeks ago (May 13, 2024), when it closed at $976.96 --Down 52.73% from its 52-week closing high of $1201.76 on Aug. 27, 2024 --Up 7.64% from its 52-week closing low of $527. ...